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1. Introduction 
1.1 Methadone and methadone maintenance therapy (MMT): An overview 
Methadone acts on the opioid receptors and produces many of the same effects of morphine 
and heroin. In the treatment of opioid dependence, methadone has cross-tolerance with 
other opioid, including heroin and morphine and a long duration of effect. Higher doses of 
methadone can block the euphoric effects of heroin, morphine, and similar drugs. As a 
result, properly dosed methadone patients can reduce or stop altogether their use of these 
substances.  
Methadone is a misunderstood drug and ignorance about it is common. Even professionals, 
physicians and pharmacists who are supposed to be the “guardians” of MMT receive very 
little training about the very medication that they are responsible for. To compound the 
issue, addiction is mostly viewed not as a disease and its care is frequently relegated to the 
lay public, at least until very recently. In Malaysia, addiction has solely been under the 
charge of “Agensi Anti Dadah Kebangsaan” (AADK), an agency that has mainly adopted a 
criminal approach to addiction. However, this has recently changed in Malaysia. Addiction 
is now recognized as a medical illness, under the purview of the medical professionals.  
Nevertheless, many in the medical profession only have a rudimentary understanding of 
addiction. Most physicians, pharmacists and nurses receive very little training about 
addiction and much less regarding methadone. Thus, generally, both medical and other 
caregivers have very limited knowledge about addiction and much less about methadone. 
They have generally been taught to approach addiction as a character disorder and 
administer methadone as a substitute.  
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1.2 Pharmacogenetic of methadone 
Methadone has variable pharmacology. It binds to the µ-opioid receptor, the NMDA 
ionotropic glutamate receptor to exert its effects. Its metabolism is mediated by several 
enzymes including CYP3A4, CYP2B6 and CYP2D6, enzymes that are polymorphic and 
hence exhibit great variability. It is mainly administered through the oral route and adverse 
effects include hypoventilation, constipation and miosis, in addition to tolerance, 
dependence and withdrawal difficulties.  
As a full µ-opioid agonist, methadone exhibits all the opiate-like effects. Furthermore, its 
binding to the glutamatergic NMDA (N-methyl-D-aspartate) receptor. This makes it a receptor 
antagonist against glutamate which is the primary excitatory neurotransmitter in the CNS. 
NMDA receptors modulate long term excitation and memory formation. NMDA antagonists 
such as dextromethorphan (DXM), ketamine, tiletamine and ibogaine have been studied for 
their role in decreasing the development of tolerance to opioids and as possible for eliminating 
addiction /tolerance /withdrawal. Its action on the NMDA has been proposed as a 
mechanism by which methadone decreases craving for opioids (Xiao et al, 2001). 
Methadone is a lipophilic drug and requires biotransformation for elimination. It has a slow 
metabolism and is longer lasting than morphine-based drugs. Typically its elimination half-
life ranges from 15 to 60 hours with a mean of around 22 hours. Due to the polymorphic 
nature of its metabolism, its metabolism rates vary greatly between individuals, up to a 
factor of 100. This variability is apparently due to genetic variability in the production of the 
associated enzymes CYP3A4, CYP2B6 and CYP2D6. Several studies have been conducted to 
explain the intra- as well as inter-individual variability in methadone’s pharmacokinetic and 
clinical response. Typically, methadone is a substrate for several CYP450 enzymes as well as 
P-glycoprotein (PGP). Many Single Nucleotide Polymorphisms (SNPs) have been reported 
to contribute to its variability. Furthermore, as it binds to µ-receptors, SNPs in OPRM gene 
that encodes for these receptors may contribute to the clinical response in MMT patients. 
Thus, SNPs in OPRM gene, CYP gene and ABCB1 (MDR1) gene may contribute to 
determine the clinical outcomes of the MMT (Lötsch et al, 2009). 
1.3 Pharmacokinetic of methadone 
The pharmacokinetic parameters of methadone were first published in 1975 (Verebely et al, 
1975). Methadone is a lipophilic basic drug with a pKa of 9.2, which is administered orally 
in a racemic mixture. There is strong evidence that the enantiomers differ in their 
distribution and elimination, though the majority of the studies were carried out on the 
racemic mixture. It has been suggested that methadone undergoes adaptive changes during 
chronic use according to the administered doses.  
 
 
Fig. 1.1. Methadone, (RS)-6-(Dimethylamino)-4,4-diphenylheptan-3-one 
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Several attributes have been suggested such as clearance and CYP3A4. Accordingly, several 
pharmacokinetic studies have been carried out to investigate whether therapeutic drug 
monitoring (TDM) is effective as a clinical endpoint, on the one hand, and to study the 
methadone kinetic profile, on the other. There has been suggestive evidence to non-
frequently monitor the kinetic of methadone to explain some unpredicted clinical response 
(Loimer and Schmid, 1992; Schmidt et al, 1993; Wolff and Hay, 1994; de Vos et al, 1996). It 
may be useful especially when all other measures have been taken adequately and a patient 
still cannot hold on methadone with high doses.  
It should be noted that methadone Cp cannot be used directly to describe the clinical 
response, as a certain time is required for the drug to distribute adequately in the nervous 
system. Thus, some researchers have suggested the use of an effect-compartment or link-
model to describe the effect appropriately (Ekblom et al, 1993). So far, only four studies have 
modeled methadone by this approach and only one among them for MMT patients (Dyer et 
al, 1999). It was noticed that there is an inverse relationship between plasma concentrations 
and withdrawal scores and pupil diameters. On the other hand, there was a direct 
relationship between plasma concentrations and pain threshold in the same patients. The 
area under the curve did not differ between those who reported withdrawal symptoms and 
those who did not. The study suggested that there is correlation between methadone clinical 
responses and changes in the plasma levels for methadone racemic mixture. 
1.3.1 Absorption 
The absorption of methadone following oral administration is fast and almost complete. The 
mean time to achieve peak concentration ranges from 2.5 - 30 hours depending on the 
formulation (Wolff et al, 1991). Oral bioavailability of methadone may range from as little as 
45 percent up to 90 percent following a single dose (Meresaar et al, 1981). As methadone is a 
basic drug, acid secretions may contribute to such huge variability (Kukanich et al, 2005).  
1.3.2 Distribution 
Being a lipo-soluble drug, methadone distributes widely in body tissues such as: liver, lung, 
kidney, gut, brain, and muscle with different distribution coefficients (Sawe, 1986). In opioid 
addicts, the volume of distribution at a steady state (Vss) ranged from 0.2 to 9.2 L/kg. On 
the other hand, in patients with chronic pain, Vss ranged from 1.71 to 5.34 L/kg (Inturrisi et 
al, 1990), though higher doses are usually given in such situations. 
Methadone pharmacokinetic is described as a two-compartment model. Although there are 
wide differences in the reported clearance, the reported terminal half-life was estimated to 
range from 23-26 hours. Half-life depends also on the volume of distribution, making the 
explanations much more complicated and inconclusive (Eap et al, 2002; Li et al, 2008) 
Methadone binds to plasma protein to a high degree of 86 percent, predominantly to acute 
┙-glycoprotein (AAG) (Romach et al, 1981; Eap et al, 1990). AAG is an acute phase protein 
that exhibits significant variations in its plasma levels according to the physiological and/or 
pathological situation of the patient (Fournier et al, 2000; Yang et al, 2006; Mestriner et al, 
2007). AAG levels are significantly increased in stress, leading to very low concentrations in 
the free fraction (fu) of methadone in cancer patients compared to healthy participants 
(Abramson, 1982; Gómez et al, 1995). Therefore, some studies have measured the 
concentration of AAG itself to study the impact of their concentration on methadone 
concentration and / or clinical outcomes. Rowland and Tozer (1995) have stated that ‘after a 
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rapid input of methadone, a decrease in fu will be indicated by an increase in Cp, because 
Vss is proportional to fu. On the other hand, Cu levels remain unchanged. So, if the Cu is 
the pharmacologically active concentration, a decrease in fu will not modify the maximum 
response. Thus, it has been suggested that AAG is significantly higher in patients exhibiting 
abstinence syndrome compared to those who are stable (Garrido et al, 2000) and AAG may 
contribute to the variations in methadone plasma levels.  
Other factors that may contribute to variability include age and sex. It has been suggested 
that these factors may explain about 33 percent of the inter-individual variations in Vss. 
These parameters are found to be higher in females and they are directly related to weight 
(Wolff et al, 2000).  
Furthermore, it has also been suggested that a time-dependent increase in methadone 
clearance may result from auto-induction of its own metabolism by CYP3A4, and the change 
in Vss may be due to up or down-regulation of AAG (Rostami-Hodjegan et al, 1999). 
Therefore, a time-dependent decrease in Vss may be associated with the observed time-
dependent increase in AAG.  
1.3.3 Elimination 
Generally, there is a huge inter-individual variability in methadone clearance that can reach up 
to 20 -100 folds in magnitude (Eap et al, 2002; Li et al, 2008). Methadone is eliminated by 
hepatic metabolism and renal excretion. It has been shown that at urinary pH of six and above, 
renal clearance accounts for four percent only. However, when urinary pH was lower than 6, 
the clearance of unchanged drug will be increased by 33 percent (Rostami-Hodjegan et al, 
1999). It was concluded that, about 20-50 percent of the inter-individual variability can be 
explained by urinary excretion (KuKanich and Borum, 2008). With regard to hepatic clearance, 
methadone can be recognized as a drug with a low extraction ratio, 0.16 in MMT patients. 
2. Objective of clinical study 
2.1 General objective 
To investigate factors that influence successful MMT in opiate-dependent individuals, 
2.2 Specific objective 
To investigate the impact of daily clinical methadone dose on plasma concentration of 
methadone.  
3. Clinical study 
The study involves opiate-dependent individuals who consented, met our study criteria and 
were invited to participate in the study. The study involved them taking prescribed doses of 
daily methadone according to Methadone Maintenance Therapy (MMT) guidelines 
prepared by the Malaysian Ministry of Health and be monitored regularly based on our 
study protocols. They were followed up for 12 months during the study period. At follow 
up, 5 ml of venous blood were drawn for the determination plasma methadone level using 
in-house methadone ELISA kit.  
However, at 12th month follow up, 88 out of the 128 participants fail to meet the inclusion 
criteria. Thus, in order to assess the efficacy of low dose methadone on the withdrawal effect 
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and sleeping quality, a subset of only 40 patients was further selected to participate. They 
were given a fixed 40 mg daily dose of methadone. Their withdrawal score and sleeping 
quality were assessed during the fourth week of the study.  
4. Results 
One hundred and twenty eight patients were enrolled for this pilot study. Their doses were 
titrated appropriately as tolerated. However, at 12th month follow up, 88 patients out of the 128 
participants fail to meet the inclusion criteria. Thus, in order to assess the efficacy of low dose 
methadone on the withdrawal effect and sleeping quality, a subset of only 40 patients was 
further selected to participate where they were given a fixed 40 mg daily dose of methadone. 
Daily dose averaged 57.2 mg (SD ± 22.7) (Table 4.1) and ranged from 20 to 160 mg per day 
(Figure 4.1). The corresponding plasma methadone concentration averaged 281.3 ng/ml (SD 
± 567.9) (Table 4.1) and ranged from 0 to 4634 ng/ml (Figure 4.2, Figure 4.3) 
 
 Daily Dose,(mg) Plasma Concentration, (ng/ml) 
Mean 57.19828 299.842 
Standard Error 2.110416 57.0856 
Median 50 180.8249 
Standard Deviation 22.72988 582.1612 
Sample Variance 516.6473 338911.6 
Kurtosis 2.263482 39.11501 
Skewness 1.040586 5.905204 
Table 4.1. The Summary of Statistics, Daily Methadone Dose (mg) and Plasma Methadone 
Concentration (ng/ml) 
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Fig. 4.1. Daily Methadone Dose in the Study Patients 
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Fig. 4.2. Plasma Methadone Concentrations (ng/ml) as a function of daily methadone dose 
in the studied patients (outlying concentrations were removed). 
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Fig. 4.3. Plasma Methadone Concentrations (ng/ml) as a Function of Daily Methadone Dose 
(mg) in the Studied Patients 
Both the daily doses and the resulting plasma concentrations showed a non-normal 
distribution, more so for the plasma concentrations compared to the daily dose. Thus, 
although the daily dose averaged 57 mg, its median was lower at 50 mg. Similarly, although 
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plasma concentration averaged 300 ng/ml, its median was only 181 ng/ml. A closer look 
revealed that 33% of patients had doses of 40 mg/day or lower, 54% received 40 – 80 
mg/day dose and only 13% had doses 80 mg or more per day. In terms of plasma 
methadone, most, 84%, had concentrations of 400 ng/ml and 16% had 400 ng/ml and above, 
400 ng/ml being the proposed minimum concentration for effectiveness. Six percent of 
patients on the other hand, had potentially toxic concentrations of more than 700 ng/ml. 
(Table 4.2 and Table 4.3) 
 
Statistics Day 1      Day 7     Day 14    Day 21 
Mean 136.25 242.91 196.94 216.52 
Standard Error 13.49 21.13 18.27 19.66 
Median 135.06 194.12 162.05 190.25 
Standard Deviation 80.92 126.79 109.65 117.96 
Sample Variance 6548.10 16075.43 12022.56 13913.47 
Skewness 0.56 1.08 2.14 2.35 
Range 317.65 463.53 573.99 584.88 
Minimum 14.09 92.36 60.66 81.16 
Maximum 331.74 555.89 634.65 666.04 
Table 4.2. Plasma Methadone Concentrations (ng/ml) on Days 1, 7, 14 and 21 While Patients 
Received MMT 40 mg Daily 
 
Plasma 
Methadone, 
up to mg/ml 
Day 1 Day 7 Day 14 Day 21 
N Cumulative 
% 
N Cumulative 
% 
N Cumulativ
e % 
N Cumulativ
e % 
100.00 10 32.26% 2 6.06% 0 0.00% 1 3.85% 
200.00 10 64.52% 16 54.55% 17 56.67% 11 46.15% 
300.00 10 96.77% 7 75.76% 5 73.33% 8 76.92% 
400.00 1 100.00% 3 84.85% 7 96.67% 4 92.31% 
500.00 0 100.00% 1 87.88% 0 96.67% 1 96.15% 
600.00 0 100.00% 4 100.00% 0 96.67% 0 96.15% 
700.00 0 100.00% 0 100.00% 1 100.00% 1 100.00% 
800.00 0 100.00% 0 100.00% 0 100.00% 0 100.00% 
Table 4.3. Plasma Methadone Concentrations (ng/ml) on Days 1, 7, 14 and 21 While Patients 
Received MMT 40 mg Daily 
The Subjective and Objective Withdrawal Score from patient taking MMT 40 mg daily was 
poorly manifested (Figure 4.4 and Figure 4.5). It showed that methadone at 40 mg a day was 
not adequate to suppress the withdrawal from opiate dependence. 
Subjective withdrawal scores (SOW) were determined at four weeks for patients given 40 
mg daily dose of methadone. Scores averaged 32 (SD ±10.4). The lowest score was 11 and 
the highest 51. Objective withdrawal scores (OOW) were also determined at four weeks for 
patients given 40 mg daily dose of methadone. Scores averaged 8.2 ( SD ±1.5 ).  
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Fig. 4.4. Subjective Objective Withdrawal Scores from Patients Taking MMT 40 mg daily 
 
R = 0.069, SOW
R = 0.0721, OOW
0
5
10
15
20
25
30
35
40
45
50
0 2000 4000 6000 8000 10000 12000
Plasma Methadone, ng/ml
W
it
h
d
ra
w
a
l 
S
c
o
re
s
Series1
Series2
Linear (Series1)
Linear (Series2)
 
Fig. 4.5. Withdrawal Scores as a Function of Plasma Methadone Concentrations  
(Series 1 = SOW; Series 2 = OOW) 
5. Discussion 
Methadone has a complex pharmacology. There is widespread “opiophobia” and it is 
frequently perceived negatively by physicians, patients and the society so much so that many 
just accept it as a necessary evil. The complex pharmacology and “opiophobia” present a great 
challenge to patients, physician and programs in terms of finding the most appropriate dose to 
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achieve the desired results. This study was an attempt to comprehensively look at MMT. 
Among our notable findings included the variable ages of our patients, the male 
predominance, the variable daily methadone doses used and the importance of high daily 
maintenance dose, the variable plasma methadone obtained and its poor correlation with daily 
doses. Eighty eight patients were excluded from plasma concentration of methadone because 
they did not comply with the protocol. We investigated only 40 patients for the outcomes of 
MMT when the daily dose was fixed at 40 mg. We found that this daily dose was associated 
with high withdrawal scores implying failure of therapy.  
In our clinical study, initially we enrolled 128 patients. They comprised of heroin/opiate 
dependent individuals receiving MMT in our clinics. As have been observed in many 
previous studies with MMT, patients enrolled in this study were mostly males with most in 
the productive age group. The youngest was 20, the oldest 56 years old. They were also 
mainly Malays. This fact underscores the importance of proper management of drug use 
disorder. These young and otherwise healthy males, if not successfully managed, are lost to 
the society and may lead a criminal life to feed their habits, given the difficulties, stigma and 
discrimination they face to be employed. Thus, instead of becoming the work force of the 
country needed to generate economic activity, these youngsters in turn add the burden of 
the country. There will be added burdens in terms of law enforcement costs, judiciary costs 
and other related costs. This would be over and above other costs like the society and 
health-care costs.   
Of note was a high prevalence of HIV positivity at 36%. In most countries with good harm 
reduction programs for injecting drug users, the prevalence of HIV positivity is generally 1-
2% (Central Intelligence Agency). The high prevalence seen in our cohort underscores the 
need for urgent effective measures. As there is no cure for HIV/ AIDS, this high prevalence 
would mean that many young Malay males in Malaysia would eventually succumb to the 
disease. This would reduce the pool of available males for population growth and if this is 
allowed to go on unabated, this will impact on the demography of the Malaysian 
population. Ethnic proportions can change and population growth in some communities 
may be halted. They may face troubles to obtain gainful employment and may resort to 
crimes to feed their habits, themselves and may be even their families. Co-morbid 
conditions like psychiatric illnesses and stigma and discrimination may make them 
dangerous to self, family and the society. 
No age is however spared by the drug use disorder. The youngest of our patients was a 20 
year-old. They began their drug habit as early as when they were 12 years. The oldest patient 
was 56 years of age and the oldest age a patient started with the habit was 32 years. Drug use 
disorder is a chronic relapsing disease. The duration of illness among our patients ranged from 
two years to 38 years and averaged 13 years. These have implications. For one, preventive 
measures for drug use disorder must begin early and should be continued through all ages. 
Patients afflicted with the disease should also have long follow ups as they evidently continue 
with their habits right through their golden years. The longer they continue on the habit, the 
greater is the chance for them to contract diseases like HIV, if they have not yet been infected. 
Being young and otherwise healthy, young addicts may find themselves constrained in 
various activities and this may lead them to many unhealthy practices. 
Drug users do not live in isolation. They have sexual partners and families. Apart from 
transmission through the sharing of injection equipments, having the HIV reservoir, drug 
users can also transmit the disease to their sexual partners, through penetrative sex. Thus, 
what started as a concentrated epidemic among drug users is now showing evidence for a 
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more generalized epidemic into the community through sexual transmission. In the 
beginning, less than one percent of HIV victims were females. Now it stands at about 20% 
and this clearly demonstrates the generalization of the HIV epidemic in Malaysia that began 
as a concentrated epidemic among drug users. Most of the afflicted females are also wives 
and spouses of drug users who are themselves HIV positive and not sex workers as many 
would have expected. There is however evidence for a growing epidemic among sex 
workers and this again has the potential to generalize into the community. 
For the forty patients studied, their daily dose averaged 57.2 mg and ranged from 20 to 160 
mg per day. Median dose was 50 mg per day. The corresponding plasma methadone 
averaged 281.3 ng/ml. It ranged from 0 to 4634 ng/ml. Daily methadone doses poorly 
predicted resulting plasma methadone concentrations, a hallmark for a drug metabolized by 
genetically polymorphic enzymes. Indeed when we measured plasma methadone 
concentrations in patients who received a fixed 40 mg daily methadone , they varied from 14 
ng/ml to 331 ng/ml, a 23-fold difference. It is thus evident that no one dose fits all. As with 
many drugs used in the management of chronic diseases, methadone doses should be 
individualized to optimum outcomes that must be determined objectively.  
It is also interesting to note that, despite claims by many physicians that relatively lower 
doses of methadone would be sufficient for our Malaysian patients, our observation of high 
withdrawal scores among patients who were maintained at 40 mg daily of methadone 
would imply this was not so. Severe withdrawal would discourage patients from remaining 
on treatment and by inference, they will not be retained. Indeed it has consistently been 
found  that a sufficiently high dose of substitution therapy was required for improved 
outcome (Brady et al, 2005). High doses of methadone were significantly more effective in 
suppressing illicit heroin use and in retaining patients in the program (Family Health 
International; Mattick et al, 2003) and in producing optimum outcomes (Farré et al, 2002).  
Inadequate doses and premature termination are the greatest threats to a successful MMT 
program in Malaysia. Malaysian doctors may outwardly say that they use lower methadone 
doses because of their fear for ethnic difference that would put their patients at higher risks 
for toxicity if they were to use doses as high as those recommended by the Western 
literature. What they may not want to admit is the fact that, inwardly, they have fears with 
methadone (and all opiates actually!) just for the simple reason that methadone is an opiate, 
just like the dreaded heroin and morphine! Indeed Malaysian doctors are not alone in this. 
Many doctors everywhere share the same view. Thus, despite ample evidence for the need 
to maintain patients at a daily dose of 80 mg to 100 mg, most patients are maintained on 
much less, and many are encouraged early termination.  
It is probably understandable that the lay public may not understand the scientific basis for 
MMT and could be disparaging and become critical of it. It is however less clear why many 
physicians and other health care providers have the same views. Even those directly 
involved with MMT programs frequently fail to adhere to the basic principles of MMT. Most 
have actually received clear information on the pharmacologic principles underlying MMT 
and their claim that they want to prescribe as few medications as possible sound hollow, as 
they frequently easily prescribe other mood altering drugs, such as the benzodiazepines that 
are often prescribed with abandon and can produce psychological and physiologic 
dependency. Even if they claim they fear adverse effects, the adverse, physiologic effects of 
MMT are minimal and methadone is probably associated with the least side effects of any 
drug in a physician's pharmacologic armamentarium, when used appropriately. The real 
reason is probably more to do with the general “opiophobias” as it is known that some 
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doctors even hesitate to use opiates even when indications are clear. Efforts should therefore 
be made urgently to reeducate these doctors. In their hands is the future of the nation. Their 
failure to prescribe adequate methadone doses will lead to therapeutic failure for MMT. This 
has dire consequences.  
There is another problem. The expectation of the public, doctors and patients as regards 
treatment of addiction is to have a drug-free ending. This puts extra pressures on the doctor 
and patient alike and this will encourage doctors and patients to use low doses for the 
shortest possible time. This is despite the fact that maintenance therapy for at least two years 
with adequate doses is known to be associated with the maximum chance of remaining 
abstinent when methadone has been tapered. Many patients can thus receive less than two 
years of treatment with methadone with encouragements to discontinue maintenance 
frequently coming from health care providers working in maintenance programs. Most 
treating doctors also often do not try to discover reasons why patients started drug in the 
first place, or the existence of comorbid psychiatric illnesses. This less than holistic approach 
to MMT can result in increased anxiety among patients that can lead to the use of other 
psycho-active drugs, such as the benzodiazepines. 
Notwithstanding the requirement for higher doses, as with any drugs, the dosing of 
methadone should be individualized (Latowsky, 2006). While low doses are associated with 
relapse and failure, too high a dose may lead to toxicities such as prolongation of QT 
interval and subsequent fatal polymorphic ventricular fibrillation (Fanoe et al, 2007). As 
regards plasma methadone concentrations, although we did not observe a clear correlation 
between plasma concentration and clinical effects, in the individual patients they may prove 
useful as illustrated in the cases we described above. Notwithstanding that, it is clear that a 
dose of 40 mg a day is generally inadequate. Subjective withdrawal scores (SOW) at four 
weeks for patients given 40 mg daily dose of methadone averaged 32 and the standard 
deviation was large at 10.4. The lowest score was 11 and the highest 51. Objective 
withdrawal scores (OOW) were also determined at four weeks for patients given 40 mg 
daily dose of methadone. Scores averaged 8.2 ( SD ±1.5 ). It is evident that severe 
withdrawals occurred in patients maintained on 40 mg daily. 
6. Conclusion 
We concluded that the variable plasma methadone obtained was poorly correlated with 
daily doses of methadone and low dose methadone was inadequate to suppress opiate 
withdrawal.  
A daily dose of 40 mg was associated with a high incidence of opiate withdrawal. Thus, 
prescription of methadone dose should be individualised to achieve a higher success of MMT.  
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